Are Wall Street Analysts Bullish on Vertex Pharmaceuticals Stock?

Boston-headquartered Vertex Pharmaceuticals Incorporated (VRTX), valued at a market cap of $123.9 billion, specializes in discovering, developing, and commercializing small molecule drugs, primarily focusing on cystic fibrosis (CF).

Shares of the biotech company have outshone the broader market in the last year. While VRTX has surged 39.3% over this time frame, the broader S&P 500 Index ($SPX) has rallied by 26.1%. In 2024, the stock rose 20.4%, compared to SPX’s 17.2% return on a YTD basis.